Jemperli performed better than Keytruda on some measures – such as tumours which express PD-L1 at levels between 1% and 49% and tumour proportion scores (TPS) above 50% – but Merck’s drug ...
The green light means that Keytruda is muscling in on territory held by GlaxoSmithKline's rival drug Jemperli (dostarlimab), which was approved for patients with recurrent or advanced endometrial ...
Keytruda has previously shown benefits in other ... Sloan Kettering in New York City found that immunotherapy drug Jemperli, ...
Hosted on MSN1mon
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerIn the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR’s earnings beat ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback